Cost-effectiveness Sequential Simulation Modeling of Fremanezumab versus Other Therapies for Migraine Prevention from Private and Public Payer Perspectives in Canada
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- This investigation assessed the cost-effectiveness of different strategies for the prevention of episodic and chronic migraine (EM and CM) considering evolving clinical practices in Canada
- This robust cost-effectiveness assessment based on published clinical evidence and evolving medical practices is the first to establish that, when compared to existing therapies used sequentially for the prevention of EM and CM, fremanezumab, a safe and effective novel anti-CGRP agent, is a cost-effective option for the prevention of EM and CM in Canada.
- Considering the significant unmet needs of patients with EM and CM, with a flexible monthly or quarterly dosing regimen, fremanezumab provides a convenient and cost-effective migraine prevention strategy for reducing the clinical and economic impact of EM and CM on patients, employers, payers, healthcare system, and society.
Presenting Author
Chander Sehgal, MD, MBA
Associate Director, Market Access
Teva Canada Innovation
Montreal, Quebec, Canada
Chander Sehgal, MD, MBA, is currently Director, Market Access at Teva Canada Innovation. In his current role, Chander leads the Market Access strategies and execution for Teva’s brand and biosimilar products, in addition to other responsibilities. Previously, Chander has worked at the Innovative Medicines Canada, CADTH, GSK Canada, Merck Canada, Pfizer Canada and Pfizer India across a variety of roles. Chander is an Oncologist by training, an MBA from the Ivey Business School, University of Western Ontario, Canada, and has a Health Economics diploma from University of York, UK.
Author disclosures
Chander Sehgal, MD, MBA: Teva Canada Innovation (Employment) (Salary)
